University of California, Irvine experts engineered glycan-dependent T cell recruiters (GlyTRs) that selectively bind tumor-associated carbohydrate antigens, enabling potent T cell-mediated killing across multiple solid cancers while sparing healthy tissues. This velcro-like binding strategy addresses longstanding challenges of differentiating cancer from normal cells and overcoming immune suppression by cancers. Preclinical models demonstrated efficacy in breast, colon, lung, ovarian, pancreatic, and prostate cancers, signalling promising broad-spectrum immunotherapy avenues.